NCT03867500View on ClinicalTrials.gov

Effects of Niacin on Intramyocellular Fatty Acid Trafficking in Upper Body Obesity and Type 2 Diabetes Mellitus

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

November 1, 2018

Primary Completion Date

December 22, 2021

Study Completion Date

December 22, 2021

Conditions
Type 2 Diabetes MellitusObesity
Interventions
DRUG

Niacin

Intravenous infusion, a titrated dose starting from 0.6 mg/min to a maximum of 2.8 mg/min (likely needed dose = 1.4 mg/min)

DRUG

Saline

Intravenous infusion of 0.9% Sodium chloride (NaCl)

Trial Locations (1)

55905

Mayo Clinic in Rochester, Rochester

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
collaborator

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

lead

Mayo Clinic

OTHER

NCT03867500 - Effects of Niacin on Intramyocellular Fatty Acid Trafficking in Upper Body Obesity and Type 2 Diabetes Mellitus | Biotech Hunter | Biotech Hunter